Cancer Research UK Scotland Institute

What Cancer Research UK Scotland Institute does

The Cancer Research UK Scotland Institute (formerly CRUK Beatson Institute) is a non-profit cancer research institute located at the Garscube Estate on the north-western edge of Glasgow. It operates as a national centre of excellence core-funded by Cancer Research UK, which committed £123 million over seven years in September 2023 to support long-term discovery and translational cancer research. The institute houses approximately 40 research groups covering cancer cell proliferation, survival and dissemination, immune engagement with cancer, tumour microenvironment biology, mitochondrial oncogenetics, and metabolism, among other areas. It is closely integrated with the University of Glasgow's basic and clinical cancer research programmes and serves as a hub for PhD studentships and the TRACC clinician-scientist training programme.

The institute's core technology platforms — branded as Advanced Technologies — include the Beatson Advanced Imaging Resource (BAIR) for light microscopy, high-content analysis and flow cytometry; translational molecular imaging; mass spectrometry-based proteomics and metabolomics; transgenic cancer models; deep phenotyping of solid tumours; molecular technology; and a bioinformatics and data science function with a dedicated data science and data management team. These platforms are delivered as shared core facilities serving the internal research groups and external collaborators. Research outputs are disseminated through academic publication, conference participation (e.g., Glasgow Cancer Seminar Series, Organoids Are Us, WntUK 2026), and commercial translation pathways via its sister organisation Cancer Research Horizons.

The institute does not operate a commercial revenue model. It is a registered Scottish charity (No SC006106) and company limited by guarantee (No 84170), funded primarily through the Cancer Research UK core grant and supplemented by additional competitive grants, commercial partnerships, and bequests such as the Annie McNab Bequest. Its governance is overseen by a Board of Directors and a Scientific Advisory Board. Outputs — scientific knowledge, publications, trained researchers, and translational candidates — flow to the wider cancer research community, clinical partners, and ultimately patients, rather than to a paying customer base.

Name

Cancer Research UK Scotland Institute

Legal name

The Beatson Institute for Cancer Research

Website

https://beatson.gla.ac.uk

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

The Cancer Research UK Scotland Institute is a Glasgow-based, non-profit cancer research institute comprising ~40 research groups, core-funded by Cancer Research UK (£123m over 7 years from 2023), conducting basic and translational cancer biology with close integration to the University of Glasgow.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Genitourinary Oncology (HLAKAFAM)

Keywords

• Cancer research
• Translational research
• Preclinical models
• Biomedical imaging
• Proteomics services

Headquarters

HQ city

Glasgow

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Marketing channels5 records

Core offering

The Cancer Research UK Scotland Institute is a non-profit cancer research institute conducting basic and translational research into cancer cell proliferation, survival and dissemination. It operates approximately 40 research groups across cancer biology and therapy, and provides advanced technology platforms (transgenic models, imaging, mass spectrometry, bioinformatics) and training programmes (PhD studentships, clinician training).

Product overview

The CRUK Scotland Institute (formerly CRUK Beatson Institute) is a cancer research institute offering a portfolio of research technologies, core facilities, and educational programmes. The core technologies include transgenic cancer models, advanced imaging (BAIR), mass spectrometry, molecular imaging, and bioinformatics services. The institute provides deep phenotyping and molecular technology capabilities, supported by laboratory operations and scientific services. Educational offerings include PhD studentships and the TRACC clinician training programme. The institute operates as a single unified research facility rather than a platform-plus-modules architecture, with technologies and services provided through dedicated core facilities and research groups.

Differentiator

Problem solved

Functional benefit

Products and services

• Transgenic Models of Cancer

Quantifiable outcome

• Understanding how cancers develop, grow and spread
• +1 more outcomes

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core.

• University of GlasgowcoreStrategic or Co-development PartnerThe institute has close ties to the University of Glasgow's basic and clinical cancer research groups. Located on the north-western edge of Glasgow with integrated operations.
• Cancer Research HorizonscoreStrategic or Co-development PartnerConnected partner organization focused on translating cancer research discoveries into new treatments and therapies for patient benefit.
• CRUK Scotland CentrecoreStrategic or Co-development PartnerAffiliated cancer research centre in Scotland working collaboratively on cancer research initiatives and discoveries.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Netherlands Cancer Institute (NKI): NKI is one of Europe's leading dedicated cancer research and treatment institutes, combining basic research with clinical oncology under a single organizational structure. Comparable in mission, scale, and the integration of discovery research with patient care.
• European Molecular Biology Laboratory (EMBL): EMBL is a multi-site European research organization in molecular life sciences, with a similar intergovernmental/charitable funding model and a focus on basic research with technology platform development. Comparable in core facility model and research group structure.
• Wellcome Sanger Institute: A UK-based genomic and cancer research institute with strong bioinformatics and large-scale biology capabilities, also core-funded by a major charitable funder. Comparable in its multi-group structure, technology-platform model, and translational ambitions.
• Francis Crick Institute: The Francis Crick Institute is the largest biomedical research institute in Europe, with major funder partnerships (CRUK, Wellcome, MRC) and a similar model of multi-group basic discovery research integrated with clinical translation. It is the most direct UK peer in terms of funding model, scale, and core technology platform approach.
• Cancer Research UK Cambridge Centre: A CRUK-designated cancer research centre in Cambridge, structurally similar to the Scotland Institute, with close integration to the University of Cambridge clinical and basic research community. Comparable as a CRUK-funded cancer research centre combining discovery and translational research.
• Cancer Research UK Manchester Institute: Another CRUK-funded cancer research institute embedded within the University of Manchester, with a similar model of multi-group cancer biology research and translational focus. Directly comparable as a peer CRUK institute with overlapping research themes.
• Institute of Cancer Research (ICR): The Institute of Cancer Research is one of the UK's leading cancer research institutes, also affiliated with the University of London. It combines basic discovery science with translational research and clinical trials, and operates core technology platforms - making it a direct peer in scope, funding model, and translational ambition.

Broad incumbents

• Broad Institute of MIT and Harvard: The Broad Institute operates at significantly larger scale, with genome-scale biology, large-scale technology platforms, and deep integration with hospital partners (MGH, Dana-Farber). Relevant as a comparable for the technology-platform-driven research model and computational biology emphasis.
• Dana-Farber Cancer Institute: Dana-Farber is a major US cancer research and treatment center with deep translational research programs and affiliated hospital. Relevant as a benchmark for the model of combining basic cancer biology research with clinical oncology, though at substantially greater scale and with more diversified funding.
• Memorial Sloan Kettering Cancer Center: MSK is one of the world's largest dedicated cancer research and treatment institutions, with far greater clinical integration and resources. It represents the upper bound of cancer research institute scale and is relevant as a benchmark for translational integration and research group productivity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/CRUK_SI
• Instagraminstagram.com/cruk_si
• LinkedInlinkedin.com/company/the-beatson-institute-for-cancer-research

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Research UK Scotland Institute